$LNAI News
Last published 2w ago
- 2w agoLNAILunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and DeregisterPR NewswireSACRAMENTO, Calif., Oct. 22, 2026 /PRNewswire/ -- Lunai Bioworks Inc. (NASDAQ:LNAI) (the "Company") announced that on October 21, 2026, it received a letter from the Listing Qualifications Department of The
- 1mo agoLNAILunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist AgreementPR NewswireLunai Bioworks, Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration...
- 1mo agoLNAILunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AIPR NewswireLunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today shared results from a technical case study conducted by its BioSymetrics...
- 2mo agoLNAILunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended ComplaintPR NewswireLunai Bioworks, Inc. (NASDAQ: LNAI) ("Lunai" or the "Company") today issued this correction to the press release the Company distributed on August...
- 2mo agoLNAILunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling SuitPR NewswireLunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today announced the filing of its Second Amended Complaint naming six registered...
- 3mo agoLNAILunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027PR NewswireLunai Bioworks Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company, today announced the execution of a Master Collaboration Agreement with ...
- 3mo agoLNAILunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud SuitPR NewswireLunai Bioworks, Inc. (Nasdaq: LNAI), an AI driven precision medicine and biodefense company, today announced the filing of its First Amended...
- 4mo agoLNAILUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERSPR NewswireFellow Shareholders, Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation...
- 5mo agoLNAILunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery CollaborationPR NewswireLunai Bioworks' (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter...
- 5mo agoLNAIFederal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common StockPR NewswireOn Wednesday, May 20, 2026, a United States District Court Magistrate Judge in Delaware granted the Motion of Lunai Bioworks, Inc. (Nasdaq: LNAI)...
- 5mo agoLNAILUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLITPR NewswireLunai Bioworks, Inc. (Nasdaq: LNAI) (the "Company") today announced that it will effect a reverse stock split of its issued and outstanding common...
- 6mo agoABBVAMGNJNJLNAI+1CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense ResearchGlobeNewswireAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a
- 6mo agoLNAIDickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against 'John Doe' 'Naked' Short-Sellers of Lunai Common StockGlobeNewswireWASHINGTON, D.C. , May 12, 2026 (GLOBE NEWSWIRE) -- via IBN -- On Monday, May 11, 2026, national law firms Dickinson Wright and Fox Rothschild joined forces to file a lawsuit on behalf of their firms' client, Lunai
- 6mo agoLNAILunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IPPR NewswireLunai Bioworks, Inc. (NASDAQ: LNAI) today announced the completion of a $20 million preferred equity issuance to acquire intellectual property assets ...
- 7mo agoLNAILunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma PartnershipsPR NewswireLunai Bioworks, Inc. (NASDAQ: LNAI) ("Lunai"), an AI-driven drug discovery company, and Geneial, Inc., a precision medicine data infrastructure and...
- 7mo agoLNAILunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under DiscussionPR NewswireLunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven drug discovery and biodefense company, today announced that its subsidiary, BioSymetrics, has...
- 7mo agoLNAILunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery ApplicationsPR NewswireLunai Bioworks, Inc. (NASDAQ: LNAI) today announced it has executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB)...
- 7mo agoLNAILunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development ModelPR NewswireLunai Bioworks (NASDAQ: LNAI), through its wholly owned subsidiary BioSymetrics, today announced the formation of a national consortium designed to...
- 8mo agoLNAILunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease SubtypingPR NewswireLunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven biotechnology company advancing precision therapeutics in central nervous system (CNS) disorders...
- 9mo agoLNAILunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBCPR NewswireLunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. Company CEO David Weinstein...
- 9mo agoLNAILunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial DataPR NewswireLunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced the launch of a new oncology collaboration with a ...
- 9mo agoLNAILunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical WeaponsPR NewswireAs global attention intensifies around the dual-use risks of advanced artificial intelligence in chemistry and biology, Lunai Bioworks (NASDAQ: LNAI) ...
- 9mo agoLNAILunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug DiscoveryPR NewswireLunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under ...
- 10mo agoLNAILunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks AdvancePR NewswireLunai Bioworks Inc. (NASDAQ: LNAI), an AI-driven pharmaceutical discovery company, was featured in International Business Times in a year-end...
- 11mo agoLNAILunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B MarketPR NewswireLunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three...
- 11mo agoLNAILunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer ModelsPR NewswireLunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has secured its first Letter of Intent (LOI)...
- 1y agoLNAILunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapyPR NewswireLunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthrough: its...
- 1y agoLNAILunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapyPR NewswireLunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthrough: its...
- 1y agoLNAILunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic CompoundsACCESS NewswireNEW YORK, NY / ACCESS Newswire / October 30, 2025 / In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. today announced
- 1y agoLNAILandmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum ProteomicsACCESS NewswirePublished in Nature Communications, a new study uncovers critical protein biomarkers that predict functional decline in Duchenne Muscular Dystrophy , opening doors to more personalized care and improved clinical
- 1y agoLNAILunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price RequirementACCESS NewswireLOS ANGELES, CALIFORNIA / ACCESS Newswire / October 16, 2025 / Lunai Bioworks, Inc. , today announced that it has regained compliance with Nasdaq's minimum bid price requirement.On April 14, 2025, Nasdaq
- 1y agoLNAILunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative PipelineACCESS NewswireLOS ANGELES, CALIFORNIA / ACCESS Newswire / October 6, 2025 / Lunai Bioworks today announced a major advance in Alzheimer's research: its AI platform, Augusta™, achieved up to a 35% improvement in
- 1y agoRENBLNAILunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and BiodefenseACCESS NewswireLOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Lunai Bioworks Inc. , a pioneer in AI-powered drug discovery and biodefense, today announced the formal adoption of its new corporate